Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Coursera Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Coursera Inc trades at $5.72 (market cap $1.64B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 24.3× Coursera Inc's market cap. Which is the better fit depends on your goals.
| ALNY | COUR | |
|---|---|---|
Market Cap | $39.89B | $1.64B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $12.70 |
52-Week Low | $278.09 | $5.09 |
Enterprise Value | $38.15B | $890.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Coursera (COUR) trades at $5.71, up 0.71% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $757.5M in 2025, though net losses persist at -$51M. The Udemy merger and a $500M share repurchase program are key developments. Cash flow from operations remains positive at $108.7M, supporting ongoing investments.
Wall Street analysts are generally optimistic with a $8.00 consensus price target, implying 40% upside. Risks include sustained profitability challenges and integration execution post-merger. The stock presents a growth opportunity if operational synergies materialize, but investors should weigh the high volatility and competitive pressures in edtech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
